February 25, 2019
Roche to acquire Spark Therapeutics for $114.50 per share representing a total equity value of $4.8 billion. Spark Therapeutics will continue its oper...
February 22, 2019
Orchard Therapeutics plc (Nasdaq:ORTX) presents Two-Year Follow-Up Data versus historical control from Registrational Trial of OTL-101 for the Treatme...
November 1, 2018
Orchard Therapeutics plc (Nasdaq:ORTX), a biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening...
August 13, 2018
Orchard Therapeutics, a leading commercial-stage company dedicated to transforming the lives of patients with rare diseases through innovative gene th...
April 13, 2018
GlaxoSmithKline (GSK) said today it will hand off its rare disease gene therapy portfolio — including its European-approved gene therapy Strimvelis™ —...
March 24, 2018
TiGenix NV (Euronext Brussels and NASDAQ: TIG) (“TiGenix”) and Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) today announced that the E...
January 5, 2018
TiGenix NV ("TiGenix") (Euronext Brussels and NASDAQ: "TIG"), an advanced biopharmaceutical company focused on exploiting the anti-inflammatory proper...
January 3, 2018
Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, today announc...
December 19, 2017
Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, announced tod...